% ============================================================================
% CONSTRAINT STORY: crispr_genomic_rewrite_2026
% ============================================================================
% Version: 1.0 (Deferential Realism Core + Directionality + Boltzmann + Network)
% Logic: 6.0 (Indexed Tuple P,T,E,S + Sigmoid f(d) + Coupling + Purity + Network)
% Generated: 2026-02-24
% Status: [ACTIVE]
% ============================================================================

:- module(constraint_crispr_genomic_rewrite_2026, []).

:- use_module(constraint_indexing).
:- use_module(domain_priors).
:- use_module(narrative_ontology).

% --- Constraint Identity Rule (DP-001: ε-Invariance) ---
% Each constraint story must have a single, stable base extractiveness (ε).
% If changing the observable used to evaluate this constraint would change ε,
% you are looking at two distinct constraints. Write separate .pl files for
% each, link them with affects_constraint/2, and document the relationship
% in both files' narrative context sections.
%
% The context tuple is CLOSED at arity 4: (P, T, E, S).
% Do not add measurement_basis, beneficiary/victim, or any other arguments.
% Linter Rule 23 enforces context/4.
%
% See: epsilon_invariance_principle.md

% --- Namespace Hooks (Required for loading) ---
:- multifile
    domain_priors:base_extractiveness/2,
    domain_priors:suppression_score/2,
    domain_priors:theater_ratio/2,
    domain_priors:requires_active_enforcement/1,
    narrative_ontology:has_sunset_clause/1,
    narrative_ontology:interval/3,
    narrative_ontology:measurement/5,
    narrative_ontology:constraint_metric/3,
    narrative_ontology:constraint_beneficiary/2,
    narrative_ontology:constraint_victim/2,
    narrative_ontology:constraint_claim/2,
    narrative_ontology:affects_constraint/2,
    narrative_ontology:coordination_type/2,
    constraint_indexing:constraint_classification/3,
    constraint_indexing:directionality_override/3,
    narrative_ontology:omega_variable/3,
    narrative_ontology:human_readable/2,
    narrative_ontology:topic_domain/2.

/* ==========================================================================
   1. NARRATIVE CONTEXT
   ========================================================================== */

/**
 * CONSTRAINT IDENTIFICATION
 *   constraint_id: crispr_genomic_rewrite_2026
 *   human_readable: CRISPR Genomic Programmability
 *   domain: technological/biological
 *
 * SUMMARY:
 *   CRISPR-Cas9 represents a phase transition in biological engineering: the
 *   ability to rewrite specific DNA sequences at scale and precision. The
 *   constraint emerges not from the technology itself but from the
 *   institutional structures around its deployment, access, and governance.
 *   CRISPR exhibits the full spectrum of Deferential Realism classifications
 *   from different perspectives. For pharmaceutical corporations and research
 *   institutions, it functions as a coordination mechanism (Rope) — a shared
 *   toolkit enabling therapeutic innovation. For patients with genetic
 *   disease, it is a mixed coordination-extraction hybrid (Tangled Rope)
 *   constrained by patent barriers and therapeutic scarcity. For populations
 *   without access to genomic medicine infrastructure, it creates a permanent
 *   genetic stratification (Snare). For future persons born with heritable
 *   CRISPR modifications, it is an irreversible imposition with zero exit
 *   options (Snare). For regulatory bodies, traditional IP and drug-approval
 *   frameworks are increasingly theatrical (Piton) — real control has shifted
 *   to developers. For the analytical observer at civilizational scale,
 *   CRISPR reveals an immutable constraint: once DNA editability is possible,
 *   it cannot be unknown (Mountain — but falsely claimed, since the
 *   structural data reveals contingent institutional extraction). The
 *   constraint's theater_ratio (0.58) reflects regulatory theater: agencies
 *   perform gatekeeping on somatic therapies while lacking effective
 *   oversight of germline research conducted offshore. The extractiveness
 *   trajectory (0.18 → 0.38) shows increasing rent-seeking as therapeutic
 *   monopolies crystallize and access inequality widens.
 *
 * KEY AGENTS:
 *   - Gene Therapy Developers & Pharma: Primary beneficiary (institutional/arbitrage) — control IP, manufacturing, and therapeutic market; capture first-mover advantage in germline editing protocols
 *   - Genetic Access Equity (Global South): Primary victim (powerless/trapped) — locked out of genomically-stratified futures by capital and infrastructure barriers; cannot opt out
 *   - Germline Modification Subjects: Primary victim (powerless/trapped) — future persons with no retroactive consent rights; irreversible heritable modification from parental decisions
 *   - Patients with Genetic Disease: Secondary victim (moderate/constrained) — benefit from therapy options but face patchy access and high costs; constrained by limited alternatives
 *   - International Regulatory & Ethics Coalitions: Organized actors (organized/constrained) — WHO, national bioethics boards, open-access advocacy; building sunset mechanisms through moratorium frameworks and equitable-access mandates
 *   - Patent & Regulatory Infrastructure: Institutional actor (institutional/arbitrage) — traditional IP/drug-approval systems; perform gatekeeping theater but lack effective control of actual deployment
 *   - Analytical Observer: Civilizational view (analytical/analytical) — risks naturalizing contingent IP/access barriers as immutable biological laws
 */

/* ==========================================================================
   2. BASE PROPERTIES (DOMAIN PRIORS)
   ========================================================================== */

% --- Numerical metrics ---
domain_priors:base_extractiveness(crispr_genomic_rewrite_2026, 0.38).
domain_priors:suppression_score(crispr_genomic_rewrite_2026, 0.42).
domain_priors:theater_ratio(crispr_genomic_rewrite_2026, 0.58).

% --- Constraint metric facts (engine primary keys, must mirror domain_priors) ---
narrative_ontology:constraint_metric(crispr_genomic_rewrite_2026, extractiveness, 0.38).
narrative_ontology:constraint_metric(crispr_genomic_rewrite_2026, suppression_requirement, 0.42).
narrative_ontology:constraint_metric(crispr_genomic_rewrite_2026, theater_ratio, 0.58).

% --- Constraint claim ---
narrative_ontology:constraint_claim(crispr_genomic_rewrite_2026, tangled_rope).
narrative_ontology:human_readable(crispr_genomic_rewrite_2026, "CRISPR Genomic Programmability").
narrative_ontology:topic_domain(crispr_genomic_rewrite_2026, "technological/biological").

domain_priors:requires_active_enforcement(crispr_genomic_rewrite_2026).

% --- Structural relationships ---
narrative_ontology:constraint_beneficiary(crispr_genomic_rewrite_2026, gene_therapy_developers).
narrative_ontology:constraint_beneficiary(crispr_genomic_rewrite_2026, pharmaceutical_corporations).
narrative_ontology:constraint_beneficiary(crispr_genomic_rewrite_2026, research_institutions).
narrative_ontology:constraint_victim(crispr_genomic_rewrite_2026, genetic_access_equity).
narrative_ontology:constraint_victim(crispr_genomic_rewrite_2026, regulatory_compliance_subjects).
narrative_ontology:constraint_victim(crispr_genomic_rewrite_2026, germline_modification_subjects).

/* ==========================================================================
   3. INDEXED CLASSIFICATIONS (P, T, E, S)
   ========================================================================== */

% PERSPECTIVE 1: GENETIC ACCESS EQUITY (SNARE) — Nations without capital for CRISPR infrastructure cannot opt out of a genomically-stratified world. Patent concentration and manufacturing barriers trap developing regions in genetic dependency. d≈0.93, f(d)≈1.40, σ=1.2 → χ≈0.64.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, snare,
    context(agent_power(powerless),
            time_horizon(generational),
            exit_options(trapped),
            spatial_scope(global))).

% PERSPECTIVE 2: GERMLINE MODIFICATION SUBJECTS (SNARE) — Individuals with heritable CRISPR modifications cannot consent retroactively; they are trapped by ancestral decisions. No exit option exists. d≈0.97, f(d)≈1.43, σ=1.2 → χ≈0.77.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, snare,
    context(agent_power(powerless),
            time_horizon(generational),
            exit_options(trapped),
            spatial_scope(global))).

% PERSPECTIVE 3: PATIENTS WITH GENETIC DISEASE (TANGLED ROPE) — Constrained by limited therapeutic alternatives and life-threatening conditions, but benefit from CRISPR therapy options when available. Access is patchy and unequal. d≈0.68, f(d)≈1.08, σ=1.0 → χ≈0.41.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, tangled_rope,
    context(agent_power(moderate),
            time_horizon(biographical),
            exit_options(constrained),
            spatial_scope(national))).

% PERSPECTIVE 4: GENE THERAPY DEVELOPERS & PHARMA (ROPE) — Primary beneficiaries with arbitrage capacity. Control IP, manufacturing, market access. Experience CRISPR as enabling technology and coordination mechanism for therapeutic pathways. d≈0.08, f(d)≈-0.10, σ=1.2 → χ≈-0.05. Net beneficiary; negative effective extraction.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, rope,
    context(agent_power(institutional),
            time_horizon(immediate),
            exit_options(arbitrage),
            spatial_scope(global))).

% PERSPECTIVE 5: REGULATORY & ETHICS COALITIONS (SCAFFOLD) — Organized actors (WHO, national bioethics commissions, open-access advocacy groups) are building sunset mechanisms: moratorium frameworks on germline editing, mandatory pre-clinical disclosure, equitable access mandates. Sees CRISPR as a temporary coordination problem with structured exit through governance maturation. d≈0.38, f(d)≈0.38, σ=1.2 → χ≈0.18.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, scaffold,
    context(agent_power(organized),
            time_horizon(generational),
            exit_options(constrained),
            spatial_scope(global))).

% PERSPECTIVE 6: PATENT & REGULATORY APPARATUS (PITON) — The classical IP/drug-approval framework (designed for chemical pharmaceuticals) is largely theater when applied to genomic tools. Patents on CRISPR components are fragmentary and contested; regulatory pathways (FDA clearance) assume somatic therapy but lack real gatekeeping for germline use. theater_ratio=0.58 shows moderate theatrical performance. Institutions persist through inertia; actual functional control has shifted to developers.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, piton,
    context(agent_power(institutional),
            time_horizon(civilizational),
            exit_options(arbitrage),
            spatial_scope(global))).

% PERSPECTIVE 7: ANALYTICAL OBSERVER / BIOLOGICAL CONSTRAINT (MOUNTAIN) — At civilizational scale, CRISPR rewrite capability reveals an immutable property: once you can edit DNA, you cannot un-know that capability. The knowledge constraint is irreversible. However, base ε=0.38 and suppression=0.42 contradict the mountain classification; this perspective risks naturalizing what is contingent institutional extraction as inherent biological limit.
constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, mountain,
    context(agent_power(analytical),
            time_horizon(civilizational),
            exit_options(analytical),
            spatial_scope(universal))).

/* ==========================================================================
   4. VALIDATION TESTS
   ========================================================================== */

:- begin_tests(crispr_genomic_rewrite_2026_tests).

test(perspectival_gap) :-
    constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, TypePowerless, context(agent_power(powerless), _, _, _)),
    constraint_indexing:constraint_classification(crispr_genomic_rewrite_2026, TypeOther, context(agent_power(moderate), _, _, _)),
    TypePowerless \= TypeOther.

test(piton_threshold) :-
    domain_priors:theater_ratio(crispr_genomic_rewrite_2026, TR),
    TR >= 0.70.

:- end_tests(crispr_genomic_rewrite_2026_tests).

/* ==========================================================================
   5. GENERATIVE COMMENTARY
   ========================================================================== */

/**
 * LOGIC RATIONALE:
 *   Extractiveness (0.38): Moderate. CRISPR enables genuine therapeutic benefit (coordination function), but institutional extraction mechanisms — patent monopolies, access barriers, pricing power — overlay coordination with asymmetric costs. The 0.18 → 0.38 trajectory shows rent-seeking intensifying as monopolies solidify and germline applications expand beyond therapy into enhancement. Not a pure snare (legitimate therapeutic coordination exists) but asymmetric extraction is substantial. Suppression (0.42): Moderate. Multiple barriers constrain access: capital requirements for infrastructure, patent licensing, regulatory complexity, technical expertise concentration, and production bottlenecks. But suppression is not total — open-access CRISPR toolkits exist, some regulatory transparency is mandatory, and therapeutic alternatives (though inferior) remain available. Theater ratio (0.58): Moderate-high. Regulatory oversight of somatic therapies shows performative gatekeeping — agencies approve therapies through standard drug review, but germline editing research happens offshore with minimal real oversight. Patent offices award overlapping, contestable claims. Ethics boards issue guidelines that lack enforcement mechanisms. The theater reflects institutional lag: governance designed for small-molecule drugs cannot effectively regulate genomic tools.
 *
 * PERSPECTIVAL GAP:
 *   This constraint demonstrates deep perspectival divergence. Gene therapy developers see transparent coordination (Rope) — CRISPR is a shared enabling technology. Regulatory bodies see theatrical gatekeeping (Piton) — real control is performative. Patients see constrained benefit (Tangled Rope) — therapy is available but unequally accessible. Global South populations see permanent exclusion (Snare) — genomic stratification is irreversible. Future persons with heritable modifications see retroactive entrapment (Snare) — ancestral decisions trap them irreversibly. The analytical observer risks seeing immutable biological law (Mountain) — 'DNA editability cannot be unknown' — but the structural data reveals this as a false summit: the actual constraint is institutional (patent concentration, manufacturing barriers, regulatory capture), not biological. The presheaf of perspectives across observation sites reveals the true structure: contingent rent-seeking dressed up as inevitable consequence.
 *
 * DIRECTIONALITY LOGIC:
 *   Gene therapy developers: Beneficiary + arbitrage → d≈0.08, f(d)≈-0.10. Net beneficiary position. Patients: Victim + constrained → d≈0.68, f(d)≈1.08. Significant extraction but not maximal; they benefit from therapy option even if unequally. Genetic access equity: Victim + trapped → d≈0.93, f(d)≈1.40. Maximum extraction; no alternative to genetic stratification. Germline modification subjects: Victim + trapped → d≈0.97, f(d)≈1.43. Absolute extraction; irreversible heritable imposition with zero exit. Regulatory coalitions: Organized + constrained → d≈0.38, f(d)≈0.38. Low effective extraction; organized actors have agency and perceive sunset path. Patent infrastructure: Institutional + arbitrage → d≈0.08, f(d)≈-0.10. Piton classification from theater, not extraction directionality. Analytical observer: analytical → d≈0.72, f(d)≈1.15. False summit risk: naturalizes contingent institutional constraint as immutable biological property.
 *
 * MANDATROPHY ANALYSIS:
 *   RESOLUTION: The mandatrophy is resolved by decomposing CRISPR into two distinct constraints: (1) CRISPR Biological Capability (mountain-like: DNA editability is intrinsically reversible but contingently irreversible once deployed heritably), and (2) CRISPR Access & Governance (tangled_rope: coordination function—therapeutic innovation—layered with extraction mechanisms—patent monopolies, manufacturing barriers, regulatory capture). The Tangled Rope classification (ε=0.38, active enforcement, beneficiaries + victims) is correct at the institutional/governance level. The false mountain perspective (claiming DNA editability is inherent constraint) is exposed as a naturalization error: the irreversibility is social (IP/regulatory), not biological. The constraint family should include a separate story (crispr_biological_capability, ε≈0.06, Mountain) documenting the actual natural law: DNA is chemically modifiable via enzymatic catalysis. The 2026 story (crispr_genomic_rewrite_2026) correctly classifies the actual constraint—institutional extraction layered on therapeutic coordination—as Tangled Rope. Mandatrophy resolved: coordination is genuine (therapeutic benefit); extraction is real (access barriers, monopolies); both are structural features of 2026 deployment.
 */

/* ==========================================================================
   6. OMEGA VARIABLES (Ω) - IRREDUCIBLE UNCERTAINTIES
   ========================================================================== */

omega_variable(
    off_target_effect_prevalence,
    'How prevalent are unintended off-target edits in somatic CRISPR therapies at clinically acceptable thresholds?',
    'Long-term follow-up studies (5+ years) of approved somatic therapies; whole-genome sequencing of edited cells; correlation with adverse outcomes',
    'If off-target rates > 1 in 10,000: significant extraction via hidden harm (victims don''t know extent of modification). If < 1 in 100,000: safety claims are credible, reducing perceived snare component.',
    confidence_without_resolution(high)
).

narrative_ontology:omega_variable(off_target_effect_prevalence, empirical, 'Prevalence of off-target genetic modifications in CRISPR therapies').

omega_variable(
    germline_editing_irreversibility,
    'What are the true long-term consequences of heritable CRISPR modifications across generational timescales (100+ years)?',
    'Longitudinal genomic surveillance of edited populations; identification of unforeseen pleiotropic effects; measurement of genetic fitness and population health metrics over generations',
    'If severe unintended consequences emerge: germline editing appears as permanent snare (irreversible harm to future persons). If minimal: regulatory scaffold becomes functional and germline editing moves toward rope/tangled_rope.',
    confidence_without_resolution(low)
).

narrative_ontology:omega_variable(germline_editing_irreversibility, empirical, 'Long-term generational consequences of germline CRISPR modifications').

omega_variable(
    patent_consolidation_trajectory,
    'Will patent fragmentation on CRISPR components persist, or will consolidated licensing (via large pharma or biotech pools) crystallize a chokepoint monopoly?',
    'Analysis of patent expiration timelines, licensing pool formation, acquisition patterns; market concentration metrics for CRISPR therapeutics',
    'If fragmentation persists: rope-dominant view (many players, coordination focus). If consolidation occurs: tangled_rope or snare classification hardens (extraction mechanism becomes visible).',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(patent_consolidation_trajectory, conceptual, 'Future consolidation of CRISPR intellectual property rights').

omega_variable(
    equitable_access_feasibility,
    'Can open-access CRISPR toolkits (CRISPR-libre, OpenCRISPR) achieve clinical parity with proprietary therapies, or do IP-gated advantages in manufacturing quality persist?',
    'Comparative clinical trial data for open vs proprietary CRISPR therapies; manufacturing cost analysis; regulatory approval rates by ownership model',
    'If open access achieves parity: scaffold perspective confirmed (sunset possible through IP expiration + open manufacturing). If proprietary always superior: genetic stratification hardens (snare deepens).',
    confidence_without_resolution(medium)
).

narrative_ontology:omega_variable(equitable_access_feasibility, empirical, 'Clinical and manufacturing equivalence of open-access CRISPR systems').


/* ==========================================================================
   7. INTEGRATION HOOKS
   ========================================================================== */

narrative_ontology:interval(crispr_genomic_rewrite_2026, 0, 6).

/* ==========================================================================
   8. TEMPORAL MEASUREMENTS (LIFECYCLE DRIFT DATA)
   ========================================================================== */

% Theater ratio over time
narrative_ontology:measurement(crisp_tr_t0, crispr_genomic_rewrite_2026, theater_ratio, 0, 0.32).
narrative_ontology:measurement(crisp_tr_t3, crispr_genomic_rewrite_2026, theater_ratio, 3, 0.45).
narrative_ontology:measurement(crisp_tr_t6, crispr_genomic_rewrite_2026, theater_ratio, 6, 0.58).

% Extraction over time
narrative_ontology:measurement(crisp_be_t0, crispr_genomic_rewrite_2026, base_extractiveness, 0, 0.18).
narrative_ontology:measurement(crisp_be_t3, crispr_genomic_rewrite_2026, base_extractiveness, 3, 0.28).
narrative_ontology:measurement(crisp_be_t6, crispr_genomic_rewrite_2026, base_extractiveness, 6, 0.38).


/* ==========================================================================
   9. BOLTZMANN & NETWORK DATA
   ========================================================================== */

narrative_ontology:coordination_type(crispr_genomic_rewrite_2026, resource_allocation).
narrative_ontology:affects_constraint(crispr_genomic_rewrite_2026, germline_heritability_modification).
narrative_ontology:affects_constraint(crispr_genomic_rewrite_2026, genetic_inequality_stratification).
narrative_ontology:affects_constraint(crispr_genomic_rewrite_2026, pharmaceutical_patent_monopoly).

% DUAL FORMULATION NOTE:
% CRISPR Genomic Programmability (2026) is a tangled_rope constraint at the institutional/governance level. It is distinct from: (1) the biological capability itself (crispr_biological_capability, ε≈0.06, Mountain), which documents DNA editability as immutable natural law, and (2) specific application constraints (germline_heritability_modification, genetic_inequality_stratification), which document downstream structural effects. This story models the governance-level constraint that governs access, IP, therapeutic deployment, and regulatory oversight.

/* ==========================================================================
   10. DIRECTIONALITY OVERRIDES (v6.0, OPTIONAL)
   ========================================================================== */

constraint_indexing:directionality_override(crispr_genomic_rewrite_2026, powerless, 0.97).

/* ==========================================================================
   END OF CONSTRAINT STORY
   ========================================================================== */
